Stay updated with breaking news from Laurent Wormser. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic...
PARIS and CAMBRIDGE, Mass., May 22, 2024 -- NANOBIOTIX , a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer,...
Updated Nanobiotix corporate strategy designed to enable long-term growth through execution of the global NBTXR3 collaboration and platforms beyond NBTXR3Alignment of intent to transfer the...
Updated Nanobiotix corporate strategy designed to enable long-term growth through execution of the global NBTXR3 collaboration and platforms beyond...